Indication
HER2-positive Solid Tumor
2 clinical trials
1 product
Clinical trial
A Phase 1b, Open-Label, Dose Escalation Study of PRS-343 in Combination With Atezolizumab in Patients With HER2-Positive Advanced or Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2022-08-11
Product
PRS-343Clinical trial
A Phase 1, Open-Label, Dose Escalation Study of PRS-343 in Patients With HER2-Positive Advanced or Metastatic Solid TumorsStatus: Completed, Estimated PCD: 2023-12-01